These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7682710)

  • 1. A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.
    Matsuda Z; Yu X; Yu QC; Lee TH; Essex M
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3544-8. PubMed ID: 7682710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus.
    Park IW; Sodroski J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):341-50. PubMed ID: 8601220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virion-targeted viral inactivation: new therapy against viral infection.
    Okui N; Kitamura Y; Kobayashi N; Sakuma R; Ishikawa T; Kitamura T
    Mol Urol; 2001; 5(2):59-66. PubMed ID: 11690549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid sequence requirements for the incorporation of the Vpx protein of simian immunodeficiency virus into virion particles.
    Park IW; Sodroski J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):506-10. PubMed ID: 8548329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 2 vpx protein augments viral infectivity.
    Kappes JC; Conway JA; Lee SW; Shaw GM; Hahn BH
    Virology; 1991 Sep; 184(1):197-209. PubMed ID: 1714662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle inhibitory effects of HIV and SIV Vpr and Vpx in the yeast Schizosaccharomyces pombe.
    Zhang C; Rasmussen C; Chang LJ
    Virology; 1997 Mar; 230(1):103-12. PubMed ID: 9126266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological study on biologically distinct vpx/vpr mutants of HIV-2.
    Piroozmand A; Khamsri B; Fujita M; Adachi A; Uchiyama T
    J Med Invest; 2006 Aug; 53(3-4):271-6. PubMed ID: 16953064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transactivation is a conserved function among primate lentivirus Vpr proteins but is not shared by Vpx.
    Philippon V; Matsuda Z; Essex M
    J Hum Virol; 1999; 2(3):167-74. PubMed ID: 10413368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.
    Wu X; Liu H; Xiao H; Kim J; Seshaiah P; Natsoulis G; Boeke JD; Hahn BH; Kappes JC
    J Virol; 1995 Jun; 69(6):3389-98. PubMed ID: 7745685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr.
    Di Marzio P; Choe S; Ebright M; Knoblauch R; Landau NR
    J Virol; 1995 Dec; 69(12):7909-16. PubMed ID: 7494303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus vpr gene encodes a virion-associated protein.
    Yuan X; Matsuda Z; Matsuda M; Essex M; Lee TH
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1265-71. PubMed ID: 2150318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of chrolamphenicol acetyltransferase to human immunodeficiency virus particles via Vpr and Vpx.
    Sato A; Isaka Y; Kodama M; Yoshimoto J; Kawauchi S; Kuwata T; Adachi A; Hayami M; Yoshi O; Fujiwara T
    Microbiol Immunol; 1995; 39(12):1015-9. PubMed ID: 8789063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of mutant Vpr/Vpx on HIV-2 assembly demonstrated by immunoelectron microscopy.
    Wan JJ; Ratner L
    Proc Natl Sci Counc Repub China B; 2001 Jan; 25(1):50-8. PubMed ID: 11254173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of vif mutations on cell-free infectivity and replication of simian immunodeficiency virus.
    Park IW; Myrick K; Sodroski J
    J Acquir Immune Defic Syndr (1988); 1994 Dec; 7(12):1228-36. PubMed ID: 7965633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication.
    Kuwata T; Igarashi T; Ido E; Jin M; Mizuno A; Chen J; Hayami M
    J Gen Virol; 1995 Sep; 76 ( Pt 9)():2181-91. PubMed ID: 7561755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.
    Liu H; Wu X; Newman M; Shaw GM; Hahn BH; Kappes JC
    J Virol; 1995 Dec; 69(12):7630-8. PubMed ID: 7494271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
    Wu X; Liu H; Xiao H; Conway JA; Kappes JC
    J Virol; 1996 Jun; 70(6):3378-84. PubMed ID: 8648668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
    Connor RI; Chen BK; Choe S; Landau NR
    Virology; 1995 Feb; 206(2):935-44. PubMed ID: 7531918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm).
    Accola MA; Bukovsky AA; Jones MS; Göttlinger HG
    J Virol; 1999 Dec; 73(12):9992-9. PubMed ID: 10559313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.